Pharma can reach physicians within the EHR, but they must send the right message at the right time, she said at an MM&M event.
How VR, nanotechnology, and 3D printing could improve the value of healthcare; 100 experimental therapies in late-stage clinical trials; Kite Pharma plans "controlled" launch of CAR-T therapy
My hope is that all of us do a better job of focusing on value.
The drugmaker's new EVP of worldwide commercial operations also talks about tackling medication access, product launches, and starting a commercial team from scratch.
J&J in talks to buy Actelion; Novo Nordisk pulls ads on Breitbart News; Takeda to market Ninlaro in Europe
Former Valeant and Philidor execs arrested; at least 1 million enroll in 2017 exchange plans; mobile game helps scientists study dementia
If Trump decides to go after pharma, politicians aren't likely to receive too many "How can you do this? Think about the children!" notes.
As humans, we trade in the credits and debits of good and bad behavior. We break diets, we resume smoking, we forget our medicine.
Trump, a critic and supporter of pharma, wins election; pharma's futures rise in election's wake; drug-pricing measure in California likely to be defeated
How pharma distributes information to doctors is changing as rapidly as how doctors prefer to receive and process such information
Today's ambitious marketers and media people want to be the ones to not only figure out how to work within the regulations but also to create better work than ever before.
Sprout investors sue Valeant; FDA raises safety concerns for Cempra's experimental pneumonia drug; NHS gets approval to prescribe eribulin to breast cancer patients
Valeant to sell stomach-drug business for $10 billion; Pfizer reports growth in third quarter; sales of hep.-C drugs drive revenue down for Gilead Sciences
Mylan was slammed by people unable to afford its lifesaving EpiPen injection device following a price hike — its response was seen as too little, too late.
Each of this year's Influencers wields significant influence at a major health-related organization and boasts high-profile accomplishments, oftentimes ahead of the aforementioned pain-of- change curve.
Takeda launched four new superheroes whose lives have been touched by inflammatory bowel disease (IBD), with the help of PR agency Ketchum.
The new TV spot was developed with CNN and Edelman.
The FDA responded to criticism from industry about its proposed research of DTC animation.
Merck Consumer Health CMO Atilla Cansun also talks about about why the company is focused on preparing society for an average lifespan of 100 years.
MS drugs top the list, led by Teva's Copaxone, Biogen's Tecfida and Avonex, and Novartis' Gilenya.
Now here comes the big question. Will the shareholders and directors of KaloBios and Allergan reward or punish their CEOs for what some may see as revenue-capping concessions?
Excedrin's #DebateHeadache was inspired by complaints the brand noticed during the first presidential debate in September.
Cleveland Clinic CEO Toby Cosgrove said at the PRWeek Conference that the pharmaceutical industry has a responsibility to manage drug costs without the government stepping in
As the effectiveness of in-person detailing wanes, how will cloud-based content solutions adapt?
Ad pushes behind brands like Gilead Sciences' hepatitis-C pill Harvoni and Allergan's IBS drug Viberzi buoyed med-surg outlays for the first six months of 2016. Cancer drugs once again were the hottest category.
The firm will handle communications for scar treatment Mederma and is already managing the product launch of cellulite-treatment product Cellfina, the 10-year anniversary of injectable Radiesse, and introducing a product line.
The company promoted Maryellen Royle to global CEO of Tonic Life Communications and Jon Clark to global CEO of Nitrogen.
Physicians are seeking beyond-the-pill services from drugmakers; Novartis debunks misconception that only smokers get lung cancer; pharma's access to docs declines
And why the stories behind thalidomide, Naprosyn, AZT, cardiology stents, and Zaltrap still resonate.
Did you know that Norman Rockwell was a medical illustrator for Merck?
- BI and Lilly face a new challenge: how to market a diabetes drug to cardiologists
- Mylan CEO defends EpiPen strategy, questions pricing model in the U.S.
- Five things for pharma marketers to know: Wednesday, December 7, 2016
- Five things for pharma marketers to know: Monday, December 5, 2016
- Matt Brown leaves Guidemark Health after merger falls through
- Omnicom merges AgencyRx, Flashpoint and three other agencies to form DDB Health
- No free lunch for docs: Sponsored meals linked to more prescriptions
- Non-profit behind Free Killer Tan wants parents to practice sun safety
- Allergan draws on A-list celebs to drive engagement
- Women in senior industry roles improve connections with patients, execs say